Introduction to HPV Immunization
Human Papillomavirus (HPV) is one of the most common sexually transmitted infections globally. Vaccination is the most effective method to prevent serious complications related to the virus.
Available Vaccines
- Gardasil 9 (9-valent)
• Covers types 6, 11, 16, 18, 31, 33, 45, 52, 58
• Prevents 90% of HPV-related cancers and warts - Gardasil (Quadrivalent)
• Types 6, 11, 16, 18
• Protects against primary oncogenic types and genital warts - Cervarix (Bivalent)
• Types 16, 18
• Focus on high-risk cancer-causing strains
Vaccination Protocols
By Age Group
• Ages 9–14: 2 doses, 6–12 months apart
• Ages 15+: 3 doses (0, 2, 6 months)
Special Cases
• Immunocompromised & HIV+ individuals: 3 doses regardless of age
Priority Groups for Vaccination
Primary Targets
• Adolescents 11–12 (optimal age)
• Youths 13–26 (catch-up)
• Immunocompromised individuals
• MSM (men who have sex with men)
• HIV-positive patients
Secondary Groups
• Adults 27–45 (case-by-case)
• Individuals with multiple partners or HPV history
Free Vaccination Program (from March 2024)
- MSM, HIV-positive, immunosuppressed, transplant recipients
- Referral by a doctor, appointment scheduling, follow-up
Clinical Effectiveness
- 90–95% protection against cervical cancer
- 85–90% against anal cancer
- Significant reduction in other HPV-related cancers
- 90% reduction in high-grade lesions (HSIL)
Safety and Monitoring
Common Side Effects
• Injection site reactions, fever, fatigue, headache
Rare Side Effects
• Allergic reactions, fainting, dizziness
Long-Term Monitoring
- Regular gynecological exams and Pap tests
- For high-risk groups: frequent HPV testing and high-resolution anoscopy
Immunocompromised Vaccination Guidelines
Primary vs Secondary Immunodeficiencies
• Primary: Congenital B/T-cell or combined deficiencies
• Secondary: HIV, chemotherapy, transplant, autoimmune diseases
Scheduling
• Before or after immunosuppression therapy with timing adjustment
Modified Regimens
• Always triple-dose, monitored antibody levels
High-Risk Conditions: HIV & Transplant Patients
- 90% of HIV+ have HPV; 50% of MSM with HIV develop precancerous lesions
- Increased risk of persistent infection and rapid progression
Optimizing Vaccination Strategies
- Early vaccination, combined preventive strategies, immune support, smoking cessation
- Monitoring antibody titers, high-res anoscopy, gynecological follow-up
Contraindications & Precautions
Absolute
• Severe allergic reaction to prior dose or components
Relative
• Low CD4 count
